UCB Wins FDA Nod for ZILBRYSQ Autoinjector, Expanding gMG Treatment Options

  • UCB's ZILBRYSQ (zilucoplan) gains FDA approval for a self-administered autoinjector option for generalized myasthenia gravis (gMG) patients.
  • The autoinjector offers a convenient alternative to the existing prefilled syringe, with 99.8% successful dose delivery in clinical trials.
  • UCB expects commercial availability of the autoinjector in Q1 2027.
  • ZILBRYSQ is the first and only macrocyclic peptide C5 inhibitor approved for this administration method in the U.S.

UCB's FDA approval for the ZILBRYSQ autoinjector underscores the growing emphasis on patient-centric drug delivery solutions in rare disease treatment. This strategic move aligns with broader industry trends toward self-administration technologies, which can improve compliance and quality of life for chronic condition patients. With two distinct gMG therapies in its portfolio, UCB is positioning itself as a key player in this niche market.

Market Adoption
The pace at which gMG patients and physicians transition to the autoinjector format will determine its commercial success.
Competitive Positioning
Whether UCB can leverage this innovation to strengthen its gMG portfolio against competitors like RYSTIGGO.
Regulatory Compliance
How UCB manages the ZILBRYSQ REMS program to mitigate risks of meningococcal infections among patients.